EDSA vs ENGN

Edesa Biotech, Inc. vs enGene Therapeutics Inc. — Valuation Comparison 2026

EDSA

Biotechnology
Edesa Biotech, Inc.
Quality
3.9
out of 10
Value Trap
24
SAFE
Price
$7.86
Last close
Models
7/13
Active
VS

ENGN

Biotechnology
enGene Therapeutics Inc.
Quality
4.1
out of 10
Value Trap
12
SAFE
Price
$1.78
Last close
Models
8/13
Active

Model-by-Model Comparison

ModelType EDSA Fair ValueEDSA Upside ENGN Fair ValueENGN Upside
Bayesian DCF Intrinsic $2.73 -65.2% $0.58 -67.6%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $0.65 -91.8% $1.92 +8.1%
Dynamic NAV Asset-Based $•••.•• ••.•% $•••.•• ••.•%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
FTNN Topology Relative $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for EDSA vs ENGN — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

EDSA vs ENGN — Which Stock Is More Undervalued?

ENGN scores higher with a 4.1/10 quality rating vs EDSA's 3.9/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Edesa Biotech, Inc. (EDSA) and enGene Therapeutics Inc. (ENGN) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

EDSA currently trades at $7.86 with a QOC of 3.9/10, while ENGN trades at $1.78 with a QOC of 4.1/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).